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Due to the important physiologic function of trivalent chromium in glucose/insulin homeostasis, some commercial
organisations promote Cr3+ supplements in maintaining proper carbohydrate and lipid metabolism; regulation of
reducing carbohydrate carvings and appetite; prevention of insulin resistance and glucose intolerance; regulation of
body composition, including reducing fat mass and increasing lean body mass; optimal body building for athletes;
losing weight; treatment of atypical depression as an antidepressant; and prevention of obesity and type 2 diabetes
mellitus. On one hand, case reports are commented as ‘nonevidence-based anecdotes’. On the other hand, a
number of independent studies warn against adverse health outcomes assigned to chromium picolinate (CrPic)
dietary application. This review analyses opinion controversies, demonstrates highly individual reactions towards
CrPic dietary supplements and highlights risks when the dietary supplements are used freely as therapeutic agents,
without application of advanced diagnostic tools to predict individual outcomes.
Keywords: Patient records, Individual profiles, Subcellular imaging patterns, Therapy response, Pre/diabetes care,
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Changing long-held beliefs is never easy
As a consequence of the accumulating clinical data and
knowledge about the epidemiology and pathological
mechanisms of the most frequent causes of morbidity and
mortality, we are currently reconsidering our view of the
origins and progression of cardiovascular, oncologic and
neurodegenerative diseases. The majority of these path-
ologies are of chronic nature: they progress from precur-
sor lesions over one or even several decades of life;
therefore, it is often too late for effective therapeutic inter-
vention. An excellent example is the epidemic scale of
type 2 diabetes mellitus witnessed in the European Union.
In most industrialised countries and countries with large
populations, the permanently growing cohort of diabetics* Correspondence: Olga.Golubnitschaja@ukb.uni-bonn.de
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use, distribution, and reproduction in any medcreates a serious healthcare problem and a dramatic
health economic burden. The estimate for diabetes preva-
lence in the years 2025–2030 is half a billion patients
worldwide (see Figure 1).
Moreover, the contemporary onset of the dominant type
2 diabetes was already observed in subpopulations of teen-
agers [3]. Severe complications secondary to early onset of
diabetes mellitus, such as retinopathy, nephropathy, silent
ischaemia, dementia and cancer (Figure 2), soon may lead
to collapsing healthcare systems [4].
Optimistic versus pessimistic prognosis in future develop-
ments of the healthcare sector depends much on diagnos-
tic, preventive and treatment approaches which diabetes
care will preferably adopt in the near future. Without
innovation in healthcare, diabetes-related complications
may cause such a dramatic level of burden that any
performance of personalised medicine will not be feasible
from an economical point of view. In contrast, effectivesee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly cited.
Figure 1 Worldwide prognosis of the epidemic scale of
diabetes. Single asterisks denote estimations as published around
the year 2000; double asterisks denote stepwise worsening prognosis
(from black circles to black diamond) as published in 2003–2008;
current prognoses are marked in red colour (adapted from [1,2]).
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geted prevention could enable rapidly ageing populations in
Europe and elsewhere to be economically effective for the
society. Therefore, it is timely to consider the integrative
medical approaches to advance pre/diabetes care utilising
the innovation by predictive diagnostics as the basis for
concomitant targeted prevention, patient profiling as the
basis for individualised treatment algorithms and medical
approaches tailored to the patient [5-8].
The message is that new guidelines should create a
robust juristic and economic platform for advanced
medical services utilising the cost-effective models of
risk assessment followed by tailored treatments focussed
on the precursor stages of chronic disease [9].
Potential role of biologically active chromium in
diabetes prevention
Chromium is an essential trace element in human physi-
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Figure 2 Severe complications developed secondary to diabetes: from
pathologic processes (adapted from [4]).depends on the oxidative states of chromium ions that
vary from bivalent to hexavalent ones. The best investi-
gated forms are trivalent and hexavalent chromium
compounds. The latter is frequently used in a variety of
industrial technologies. Chronic exposure to it has been
shown to be responsible for a spectrum of severe health
problems affecting the skin and inner organs [10]. Inves-
tigations of its carcinogenic effects are in progress at
molecular and cellular levels [11,12]. In contrast, triva-
lent chromium is considered physiologically safe and is
an essential trace metal functionally involved in several
metabolic pathways in human beings as published else-
where. The recommended daily allowance of trivalent
chromium corresponds to the range of 50–200 μg [13].
Dietary deficiency of chromium leads to disturbances in
carbohydrate metabolisms; increases risk of glucose in-
tolerance, insulin resistance, hyperglycaemia and predis-
poses to obesity and type 2 diabetes mellitus [14,15].
Controversial benefits by Cr3+ nutrient supplement
in foods
Biologically valuable forms of chromium are compounds
of trivalent chromium bound to low molecular weight
organic complexes such as oligopeptides. This recogni-
tion led to the development of a commercial branch
with Cr3+ nutrient supplements which suppose to pro-
mote or even improve health status.
What are the currently available ‘pro’ versus ‘contra’
arguments to approve/disprove potential benefits of Cr3+
nutrient supplement?
Chromium is an essential metal, but only traces of triva-
lent chromium are utilised in the human body for glucose
conversion by insulin-driven reactions in carbohydrate
metabolic pathways. Furthermore, naturally available food
sources used in well-balanced diets are capable to cover
the requirement of trivalent chromium completely: fruits,
vegetables, meat, fish, grains, brewer’s yeast, etc. [16]. Cr
deficiency cases are extremely rare, and evidence-based
biochemical justification for artificial source neededtherosclerosis, valvular calcification & degeneration,  
eration time of implanted bioprosthesis, 
yopathy, silent myocardial infarcts, sudden death  
olyneuropathy, neurodegenerative diseases 
cancerogenesis  
extensive necrosis, “diabetic foot” 
‘upstream’ (up) to ‘downstream’ (bottom) in the cascade of
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the literature. Nevertheless, due to the important physio-
logic function of trivalent chromium in maintaining
proper carbohydrate and lipid metabolism and glucose/
insulin homeostasis, some commercial organisations pro-
mote Cr3+ nutrient supplements in
 regulation of reducing carbohydrate carvings and
appetite
 prevention of insulin resistance and glucose
intolerance
 regulation of body composition, including reducing
fat mass and increasing lean body mass
 optimal body building for athletes
 losing weight
 treatment of atypical depression as an antidepressant
 prevention of obesity and type 2 diabetes mellitus.
The widely spread chemical compound used as a trivalent
chromium nutrient supplement is chromium picolinate
(CrPic). CrPic has become a very popular nutritional sup-
plement for treating type 2 diabetic, obese and diabetes-
predisposed individuals [17]. However, over a decade of
human studies with CrPic indicate that the supplement has
not demonstrated effects on the body composition of
healthy individuals, even when taken in combination with
an exercise training programme [18]. Also, a potential
weight loss by CrPic therapy has not been confirmed [19].
After the evidence-based search into the issue, the US
Food and Drug Administration concluded that the ‘rela-
tionship between CrPic intake and insulin resistance is
highly uncertain’ [20]. Furthermore, some later studies
have concluded that ‘CrPic does not improve key fea-
tures of metabolic syndrome in obese nondiabetic adults’
[21]. Nevertheless, it is reported that CrPic generates
sales for more than US$100 million annually [22]. The
CrPic supplements are freely available in numerous
forms including chewing gums, pills, sports drinks and
nutrition bars [23]. CrPic is commonly supplied in the
range of 200–500 μg as a daily dose [13]. A big advan-
tage of CrPic is its high bioavailability due to increased
absorbing capacity in human tissues compared with diet-
ary chromium [24]. However, the mechanism of action
of CrPic at molecular level is not completely understood.
In 1999, Speetjens et al. reported that CrPic cleaves
DNA molecules by a radical mechanism: in the presence
of oxygen from air and biologically available reductants,
CrPic generates hydroxyl radicals damaging DNA mole-
cules [25]. Further, organisms exposed to CrPic demon-
strate the tendency to accumulate intracellular Cr3+ ions
that may lead to long-term genotoxic effects by forma-
tion of covalent bonds to DNA [26]. Taken together,
cytotoxic, genotoxic and mutagenic effects as well as ac-
tivity damaging to the mitochondria and induction ofapoptosis have been reported for CrPic-using mamma-
lian cell cultures, Drosophila and animal models [27-30].
Potential toxicity of CrPic has raised concerns about the
safety of CrPic-related nutrient supplements.
Animal experiments to model treatment effects of CrPic
on human beings
To simulate treatment effects of CrPic, a spectrum of
models has been used. To simulate type 2 diabetes melli-
tus (DM), a well-acknowledged animal model of db/db
mice was utilised in a recent project [31]. The experi-
mental design is summarised in Figure 3.Subcellular imaging insights into CrPic therapy
Quantitative subcellular imaging by ‘comet assay’ analysis
The single-cell gel electrophoresis assay is a simple and
effective method for evaluating DNA damage in cells. It
is based on the ability of denatured, cleaved DNA frag-
ments to migrate out of the cell under the influence of
an electric field, whereas undamaged DNA remains
within the confines of the nucleoid and migrates slower.
The assessment of DNA damage is done via the evalu-
ation of the DNA ‘comet’ tail shape and migration pat-
tern. The cells are immobilised in a bed of low-melting
point agarose, on a Trevigen CometSlide™ (Gaithersburg,
MD, USA). After cell lysis, samples are treated with al-
kali to unwind and denature the DNA and hydrolyse
sites of damage. After performing electrophoresis, stain-
ing with a fluorescent DNA-intercalating dye (SYBRW
Green I; Trevigen Inc., Gaithersburg, MD, USA) is done,
and the sample is visualised by epifluorescence micros-
copy. The alkaline electrophoresis is very sensitive and
allows for the detection of small amounts of damage.
In our experiments, DNA damage was designated to
four classes based on the visual aspect considering the
extent of DNA migration as published earlier [32].
Comets with a bright head and almost no tail were clas-
sified as class I, indicating minimal DNA damage,
whereas comets with no visible head and a long diffuse
tail were classified as class IV, revealing complete DNA
fragmentation. Comets with intermediate characteristics
were assigned to classes II and III based on the ratio
R=T/r, in which T represents the comet’s tail length and
r is the radius of the comet’s head. The characteristic
value of R for class I is 1 and that for class IV is ∞
(r= 0). Comets with R values ranging between 1 <R > 3
were designated as class II. The comet classification is
demonstrated in Figure 4A. Figure 4B demonstrates
comet patterns typical for experimental group 1 (left)
with the lowest level of comets of class IV (apoptosis)
and experimental groups 5–7 (right) with the highest
level of apoptosis.
Figure 3 Experimental design to model CrPic treatment effects. Animals were arranged in eight groups. Group 1 represented the healthy
control. Group 2 was the model mice for type 2 DM. Groups 3–7 were diabetes model mice treated under individual algorithms: 5 mg/kg CrPic
from 6 weeks to 6 months of age (group 3), 10 mg/kg CrPic from 6 weeks to 6 months of age (group 4), 100 mg/kg CrPic from 6 weeks to
6 months of age (group 5), 100 mg/kg CrPic from 3 to 6 months of age (group 6), and 250 mg/kg CrPic from 3 to 6 months of age (group 7).
Kidney tissue samples were collected and stored at −80 °C till the analysis described in the below section was performed.
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individual reactions towards the highest doses of CrPic
Statistical analysis of comets in classes I (intact DNA)
and IV (apoptosis) is demonstrated in Figure 5A, B, re-
spectively. The red frame marks the experimental groups
with the highest rates of statistical deviations towards
the mean value. The highest heterogeneity is obvious for
groups 5, 6 and 7, i.e. the experimental groups with the
highest doses of CrPic applied as treatment.
DNA damage in untreated diabetic group is significantly
higher compared to healthy control group
Quantitative subcellular imaging by comet assay analysis
revealed significantly higher DNA damage in the un-
treated diabetic group compared to healthy controls (seeFigure 6) that is well in agreement with data published
and reviewed for diabetic patients [4,8].
Individuality within the untreated diabetic group
Subcellular imaging generally revealed group-specific
patterns when diabetic animals were compared with
controls, although higher heterogeneity was demon-
strated within the untreated diabetic group: in some ani-
mals, intact DNA (class I comets) was monitored,
whereas only comet classes with damaged DNA were
monitored for others (see Figure 7). This heterogeneity
clearly demonstrates an individualised reaction of organ-
isms towards diabetic condition. This is a very important
observation that corresponds well with the clinical pic-
ture of diabetes [8]. Hence, it is conclusive that the
A.  
B.  
Figure 4 Microscopic imaging. (A) Comet classes I, II, III and IV (from left to right); (B) comet pattern typical for experimental group 1
(left, low apoptosis rates) and experimental groups 5–7 (right, high apoptosis rates).
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simulate the medical condition of diabetes and investi-
gate individualised therapeutic effects.
Highly individual reaction of diabetic animals towards
CrPic dietary supplements
Despite group-specific patterns, the subcellular imaging
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Figure 5 Statistical analyses for the comet types (A) I and (B) IV (see ‘
described in Figure 3 (‘experimental design’). Analyses were carried ou
of univariable variance analysis with Bonferroni. The red box marks the grou
greatest heterogeneity within corresponding groups. The individual values
circles (for the standard deviation in groups 4 and 6) and asterisk (for the mgroup responded individually to the identical dosage of
CrPic administered and the treatment duration. Within
the diabetic groups, experimental animals demonstrated
highly individual comet patterns with respect to single
dosages and treatment algorithms. This observation is im-
portant in regard of the highly individual response to the
treatment algorithms applied. The paper concludes that
there are individual reactions of diabetic animals towards
doses and duration of CrPic treatment. This observation1       2            3     4          5              6         7 
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t using SPSS 17.0 software (SPSS, Chicago, IL, USA) by the application
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which go overboard by statistical calculations are marked with black
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Figure 6 Comparative analysis in the experimental groups. (A)
The diagram presents the mean values of the individual
experimental group for the comets of class I (intact chromosomal
DNA): axe X, group numbering (1–7); axe Y, corresponding mean
values (% of comets). The highest and lowest rates correspond to
control group 1 and untreated diabetic group 2, respectively. (B) The
diagram presents the mean values of the individual experimental
group for the ratio of comets with damaged DNA (classes III and IV)
to the comets with undamaged DNA (classes I and II). Similarly to
the diagram in (A), the highest and lowest rates of DNA damage
correspond to control group 1 and untreated diabetic group 2,
respectively. The green lines mark the level corresponding to the
mean value of the control group; in contrast, the red lines mark the
level corresponding to the mean value of the untreated diabetic
group.
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ing harmful effects of CrPic therapy [13,24-28].
The authors interpreted that CrPic treatment effects are
unpredictable for the patient cohort as a whole, due to
highly individual reactions towards therapy. Individuals
should be treated personally on the basis of individual results
going by predictive diagnostics and therapy monitoring.
Group-pecific comparative quantification of apoptosis
under CrPic treatments
All diabetic groups demonstrate apoptotic rates which
are significantly higher compared to the control group(see Figure 8). The highest rates of apoptosis were moni-
tored in the diabetic groups treated with the highest
doses of CrPic, namely in the groups 5, 6 and 7.
Assumed and registered adverse health outcomes by
CrPic treatments
Taken the above observations together, the authors con-
clude possible risks for individual long-term effects
when CrPic is freely used as a therapeutic nutritional
modality agent without application of advanced diagnos-
tic tools to predict individual outcomes.
In experimental models
In terms of potential treatments of gestational diabetes,
there is very little information about the safety of CrPic
applied as a dietary supplement in pregnant women.
However, experiments performed with CrPic adminis-
tered to pregnant mice resulted in skeletal birth defects
in the developing fetus [33].
Comparative cytotoxic and genotoxic studies of triva-
lent chromium demonstrated that the compound’s safety
depends on the ligand bound to the chromium ion [34].
Thereby, CrPic produces significantly more oxidative
stress and DNA damage compared, for example, to
niacin-bound chromium(III). The implicated toxicity of
CrPic may result in renal impairment; severe biochem-
ical, histological and morphological changes in the eye;
skin blisters and pustules; anaemia; hemolysis; tissue
oedema; liver dysfunction; neuronal cell injury; impaired
cognitive, perceptual and motor activity; enhanced pro-
duction of hydroxyl radicals; chromosomal aberration;
depletion of antioxidant enzymes; oxidative stress and
DNA damage [23,29,34-38]. Increased apoptotic effects
by CrPic were demonstrated by the authors of this study
for kidney and for circulating leukocytes elsewhere
[17,39]. Potential carcinogenic effects are assumed
[40,41].
In humans
A growing body of case reports warns against adverse
health outcomes assigned to CrPic dietary application,
whereas by others, they are interpreted as ‘anecdotal
reports’ [42]. Hence, case reports have described acute
kidney failure, liver damage and anaemia by taking high
dosage of CrPic as a dietary supplement [43,44]. Adverse
cutaneous reactions to CrPic supplements have also
been described [45].
Furthermore, there are some concerns that CrPic may
affect the levels of neurotransmitters leading to potential
risks for patients treated for depression, bipolar disorder
and schizophrenia [18]. In a broader sense, CrPic sup-
plements are hormone-related and may influence hor-
mone secretion through their function in the endocrine/















































































untreated DIABETIC group 
treated DIABETIC groups 
Figure 7 Diagram demonstrates individual reactions towards CrPic treatments in the groups of comparison (1–7, group numbering is
marked in the middle). Individual levels of intact DNA (axe X, individual numbering; axe Y, comet class I in %) are highly heterogeneous in
diabetic groups compared to control group 1. The highest level of heterogeneity is evident in groups 5, 6 and 7 with the highest doses of CrPic
supplements (see ‘experimental design’ in Figure 3) The turquoise lines mark the level corresponding to the mean value of the control group; in
contrast, the red arrows mark the level corresponding to the mean of the untreated diabetic group.
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Figure 8 Diagram presents mean values of individual
experimental groups for the comets of class IV (apoptosis): axe
X, group numbering (1–7); axe Y, corresponding mean values
(% of comets). The lowest rates correspond to control group 1
(green line); the highest rates correspond to diabetic groups treated
with high doses of CrPic, namely experimental groups 5, 6 and 7.
The red line marks the level corresponding to the mean value of the
untreated diabetic group.
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prostaglandins, such as ibuprofen, indomethacin, na-
proxen and aspirin, may increase the absorption of
chromium in the body followed by unpredictable conse-
quences such as long-term genotoxic effects caused by
formation of covalent bonds to DNA molecules [26].
Some additive medication effects may be expected if
CrPic therapy is combined with diabetes treatments,
causing blood glucose levels to dip too low.
Here, the authors are wishing to stress the point that
according to our analysis, the above listed adverse health
effects are not expected to happen to everybody. They
may occur individually with a severity grade depending on
individual predispositions but can be effectively avoided
by application of advanced diagnostic tools for the therapy
monitoring and to predict individual outcomes. Further,
the authors appeal to react effectively towards the case
reports demonstrating adverse health outcomes by artifi-
cial dietary supplements often regarded as harmless by the
public and lay media.
Conclusions and recommendations
Artificial supplements for diabetes prevention:
hype or hope?
Definitely, CrPic therapy is solely one example of several
therapy forms which currently are applied ‘across-the-
board’ in diabetes care. The administration of artificial
supplements is an attempt to prevent or at least to post-
pone the onset of type 2 diabetes in the group of risk
and with individuals who are unwilling to make prudent
changes in their diets and sedentary habits. Should this
approach be considered as the hype or the hope? Con-
sidering type 2 diabetes as a multifactorial disease, ouranswer is that the above question is rather of rhetoric
nature.
High efficacy of a balanced diet, an individually opti-
mised lifestyle and personalised treatment regiments can
hardly be substituted by a limited number of single sup-
plements to cover all the multifactorial risks such as the
upward trends of population ageing, environmental risk
factors, urbanisation, additive effects of diverse stress
factors, incorrectly chosen lifestyle including unfavour-
able nutritional habits, increasing prevalence of obesity,
low physical activity, etc.
Although ageing is the well-acknowledged factor con-
tributing to the disease’s development, there are com-
pletely new epidemiologic factors characteristic of the
twenty-first century that speed up the disease’s progres-
sion particularly in the youth and in the young adults.
Hence, it has been demonstrated that the prognosed
DM rate progression will be inversely increasing with
age (younger age = higher progression), and the youngest
group of 20–39-year-old people will be delivering the
highest rates of diabetic progression which will double
the diabetes mellitus cohort of this age group by the year
2030 compared to 2010 [47]. This is a completely new
situation and a very big challenge for most societies
around the globe, requiring special competencies of sev-
eral groups of professionals as well as innovative
approaches in healthcare and health economy.
The population at-risk for diabetes is huge and in-
creasing in a pandemic scale. One of the reasons might
be the failed attempt to prevent the disease by the appli-
cation of artificial supplements and drugs with hardly
recognised individual risks. Consequently, a multimodal
approach of integrative medicine by predictive diagnos-
tics, targeted prevention and individually created treat-
ment algorithms is highly desirable.
As discussed and reviewed earlier, more individualised
treatments are desirable in effective protection against dia-
betic retinopathy and polyneuropathy, diabetes-related
cardiovascular complications and cancer [8]. Further,
field-related research is needed to establish simplified
non-invasive diagnostic approaches for routine medical
practice which would allow for an accurate prediction of
individualised therapy risks and outcomes. A promising
technological platform has been recently created using the
detection of circulating nucleic acids in blood plasma [48]
and clinical proteomics of body fluids [49].
Targeted measures require a creation of new guidelines
that are essential to regulate (renoprotective) therapy
approaches and the application of more individualised
therapeutic modalities for advanced diabetes care. These
measures should provide a legitimate regulation for
well-timed predictive diagnostics, an effective prevention
and the creation of individualised treatment algorithms
in pre/diabetes [50].
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